Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Dudley Robinson, Miriam O’Kane & Linda Cardozo. (2023) Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives. International Journal of Women's Health 15, pages 799-811.
Read now
Read now
Martino Maria Zacchè, Sushma Srikrishna & Linda Cardozo. (2015) Novel targeted bladder drug-delivery systems: a review. Research and Reports in Urology 7, pages 169-178.
Read now
Read now
Martino Maria Zacche, Ilias Giarenis & Linda Cardozo. (2014) Phase II drugs that target cholinergic receptors for the treatment of overactive bladder. Expert Opinion on Investigational Drugs 23:10, pages 1365-1374.
Read now
Read now
Eu Kiang Sharon Yeo, Hashim Hashim & Paul Abrams. (2013) New therapies in the treatment of overactive bladder. Expert Opinion on Emerging Drugs 18:3, pages 319-337.
Read now
Read now
Umberto Leone Roberti Maggiore, Stefano Salvatore, Franco Alessandri, Valentino Remorgida, Massimo Origoni, Massimo Candiani, Pier Luigi Venturini & Simone Ferrero. (2012) Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opinion on Drug Metabolism & Toxicology 8:11, pages 1387-1408.
Read now
Read now
Alex Gomelsky & Roger R Dmochowski. (2012) Oxybutynin gel for the treatment of overactive bladder. Expert Opinion on Pharmacotherapy 13:9, pages 1337-1343.
Read now
Read now
Alex Gomelsky & Roger R Dmochowski. (2011) Update on the management of overactive bladder: patient considerations and adherence. Open Access Journal of Urology 3, pages 7-17.
Read now
Read now
Vincent R Lucente, David R Staskin & Elise De. (2011) Development of oxybutynin chloride topical gel for overactive bladder. Open Access Journal of Urology 3, pages 35-42.
Read now
Read now
Anastasios Athanasopoulos & Francisco Cruz. (2011) The medical treatment of overactive bladder, including current and future treatments. Expert Opinion on Pharmacotherapy 12:7, pages 1041-1055.
Read now
Read now
G Willy Davila. (2010) Oxybutynin topical gel in the treatment of overactive bladder. Open Access Journal of Urology 2, pages 91-98.
Read now
Read now
Articles from other publishers (22)
Martin C. Michel, Linda Cardozo, Christopher J. Chermansky, Francisco Cruz, Yasuhiko Igawa, Kyu-Sung Lee, Arun Sahai, Alan J. Wein & Karl-Erik Andersson. (2023) Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders. Pharmacological Reviews 75:4, pages 554-674.
Crossref
Crossref
Karl-Erik Andersson, Helmut Madersbacher, Waleed Altaweel, Pawan Vasudeva & Yasuhiko Igawa. 2023. Handbook of Neurourology. Handbook of Neurourology
281
315
.
Karl-Erik Andersson, Helmut Madersbacher, Waleed Altaweel, Pawan Vasudeva & Yasuhiko Igawa. 2022. Handbook of Neurourology. Handbook of Neurourology
1
35
.
Honglin Ding, Peng Zhang, Ning Li, Yili Liu & Ping Wang. (2018) The phosphodiesterase type 4 inhibitor roflumilast suppresses inflammation to improve diabetic bladder dysfunction rats. International Urology and Nephrology 51:2, pages 253-260.
Crossref
Crossref
Karl-Erik Andersson, Helmut Madersbacher, Waleed Altaweel, Pawan Vasudeva & Yasuhiko Igawa. 2019. Neurourology. Neurourology
231
259
.
Roxana Geoffrion. (2018) N o 283-Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie. Journal of Obstetrics and Gynaecology Canada 40:1, pages e33-e44.
Crossref
Crossref
Roxana Geoffrion. (2018) No. 283-Treatments for Overactive Bladder: Focus on Pharmacotherapy. Journal of Obstetrics and Gynaecology Canada 40:1, pages e22-e32.
Crossref
Crossref
Honglin Ding, Ning Li, Xiaoning He, Bing Liu, Liming Dong & Yili Liu. (2017) Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast. International Urology and Nephrology 49:10, pages 1723-1730.
Crossref
Crossref
Wenhua Liu, Lirong Teng, Kongtong Yu, Xiangshi Sun, Chunyu Fan, Chaoxing Long, Na Liu, Shuang Li, Bing Wu, Qingji Xu, Fengying Sun & Youxin Li. (2017) Design of hydrogels of 5-hydroxymethyl tolterodine and their studies on pharmacokinetics, pharmacodynamics and transdermal mechanism. European Journal of Pharmaceutical Sciences 96, pages 530-541.
Crossref
Crossref
Roxana Geoffrion. (2016) Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie. Journal of Obstetrics and Gynaecology Canada 38:12, pages S158-S170.
Crossref
Crossref
Joshua A. Cohn, Elizabeth T. Brown, W. Stuart Reynolds, Melissa R. Kaufman, Douglas F. Milam & Roger R. Dmochowski. (2016) An update on the use of transdermal oxybutynin in the management of overactive bladder disorder. Therapeutic Advances in Urology 8:2, pages 83-90.
Crossref
Crossref
Scott C. McFerren & Alex Gomelsky. (2015) Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin. Drugs & Aging 32:10, pages 809-819.
Crossref
Crossref
Karl-Erik Andersson. 2014. Bladder Dysfunction in the Adult. Bladder Dysfunction in the Adult
121
222
.
Fengying Sun, Cheng Sui, Yulin Zhou, Ximing Liu, Yanan Shi, Yi Wu & Youxin Li. (2013) Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder. International Journal of Pharmaceutics 454:1, pages 532-538.
Crossref
Crossref
Christopher R ChappleAlex GomelskyRoger R Dmochowski. 2013. Contemporary Management of Overactive Bladder. Contemporary Management of Overactive Bladder
24
37
.
Roxana Geoffrion, Danny Lovatsis, Jens-Erik Walter, Queena Chou, William Easton, Annette Epp, Roxana Geoffrion, Marie-Andrée Harvey, Annick Larochelle, Kenny Maslow, Grace Neustaedter, Dante Pascali, Marianne Pierce, Jane A. Schulz, Vyta Senikas & David Wilkie. (2012) Treatments for Overactive Bladder: Focus on Pharmacotherapy. Journal of Obstetrics and Gynaecology Canada 34:11, pages 1092-1101.
Crossref
Crossref
Gary G. Kay, David R. Staskin, Scott MacDiarmid, Marilyn McIlwain & Naomi V. Dahl. (2012) Cognitive Effects of Oxybutynin Chloride Topical Gel in Older Healthy Subjects. Clinical Drug Investigation 32:10, pages 707-714.
Crossref
Crossref
Gary G. Kay, David R. Staskin, Scott MacDiarmid, Marilyn McIlwain & Naomi V. Dahl. (2012) Cognitive Effects of Oxybutynin Chloride Topical Gel in Older Healthy Subjects. Clinical Drug Investigation, pages 1.
Crossref
Crossref
Donna J. Sellers & Russ Chess-Williams. 2012. Muscarinic Receptors. Muscarinic Receptors
375
400
.
Doreen E. Chung. (2010) Topical Pharmacotherapy for Overactive Bladder. Current Bladder Dysfunction Reports 6:1, pages 20-24.
Crossref
Crossref
Anastasios Athanasopoulos & Konstantinos Giannitsas. (2011) An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder. Advances in Urology 2011, pages 1-8.
Crossref
Crossref
G. Willy Davila. (2010) Transdermal Oxybutynin: What Role in the Management of Overactive Bladder?. Clinical Medicine Insights: Therapeutics 2, pages CMT.S2608.
Crossref
Crossref